Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Conditions
Keywords
heart-assist device
Brief summary
The purpose of this study is to determine the proportion of subjects who have sufficient improvement in ventricular function after undergoing a standardized Left Ventricular Assist Device (LVAD) plus pharmacologic recovery treatment and testing protocol to allow removal of the LVAD within 18 months.
Detailed description
The encouraging results from the LVAD based recovery series suggest that the significant hemodynamic unloading provided by the Mechanical Circulatory Support (MCS) in conjunction with aggressive pharmacological treatment may induce a profound reverse structural remodeling and in turn result in a curative alternative to a specific patient population with severe heart failure. The active identification and characterization of the patients with a high potential for full cardiac function recovery is of paramount importance. The development of a standard and simplified recovery protocol would ultimately lead to a larger bridge to recovery patient population. The primary objective of this study is to determine the proportion of subjects who have sufficient improvement in ventricular function (remission from heart failure) after undergoing a standardized LVAD plus pharmacologic recovery treatment and testing protocol to allow removal of the LVAD within 18 months. The secondary objectives of this study are twofold, first to determine the durability of sustained remission from HF following LVAD explantation at 12 months and up to 3 years and second to determine the predictors of recovery.
Interventions
The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
Sponsors
Thoratec Corporation
University of Louisville
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 59 Years
Healthy volunteers
No
Inclusion criteria
1. Subject age between 18 - 59 years, inclusive 2. Subject indicated for DT or BTT 3. Subject with severe clinical heart failure resistant to intensive medical therapy and requiring LVAD implantation 4. Subject with LVEF \< 25% and cardiomegaly at the time of LVAD implantation as documented by radionuclide or contrast ventriculography or by echocardiography 5. Subject with non-ischemic etiology (confirmed by angiography either within 2 years of implantation or prior to explantation) 6. Subject have undergone HM II implantation within prior 4 weeks or planned for a HM II implant 7. Subject has a history of HF \< 5 years.
Exclusion criteria
1. Subject has evidence of active acute myocarditis confirmed by histology 2. Subject has a history of previous CVA resulting in significant fixed motor deficit limiting ability to perform exercise testing 3. Subject has been implanted with a mechanical aortic and/or mitral valve(s) 4. Subject had an aortic valve closure 5. Subject diagnosed with a hypertrophic obstructive cardiomyopathy or sarcoidosis 6. Subject with LVEDD below normal confirmed by surface echocardiogram (restrictive cardiomyopathy) 7. Subject has irreversible multi-organ failure 8. Pregnant or lactating women or unwilling to utilize two reliable methods of birth control for women of childbearing age 9. Subject is diagnosed with a psychiatric disease, irreversible cognitive dysfunction or poor psychosocial issues that is likely to impair compliance with the study protocol 10. Subject with any condition, other than heart failure, that could limit survival to less than 2 years 11. Subject has a history of cardiac or other organ transplant 12. Subject is contraindicated to anticoagulation antiplatelet therapy 13. Subject requires acute or chronic renal replacement therapy (e.g. chronic dialysis) within 3 months prior to enrollment 14. Subject participating in any other clinical investigations involving another Mechanical Circulatory Support (MCS) device or heart failure related drug, or investigations which are likely to confound study results or affect study outcome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of subjects who experience LVAD removal and subsequent freedom from mechanical circulatory support or heart transplantation | 12 months |
Secondary
| Measure | Time frame |
|---|---|
| Changes in maximal and sub maximal exercise capacity | 12-18 months |
| Changes in renal function and hepatic enzymes | 6 weeks, 3, 4, 5, 6, 9, 12-18 months |
| Changes in EF measured at 6000RPM. | 6 weeks, 4, 6, 9, 12-18 months |
| Predictors of recovery and device removal | 6 weeks, 3, 4, 5, 6, 9, 12-18 months |
| The proportion of evaluable subjects meeting explant criteria and subsequently explanted | 6 weeks, 3, 4, 5, 6, 9, 12-18 months |
| The time course of reverse remodeling on a left ventricular assist device | 6 weeks, 3, 4, 5, 6, 9, 12-18 months |
| The time course and sustainability of reverse remodeling following LVAD explantation | 12-18 months |
| Changes in quality of life, as measured by the EuroQoL (EQ5D) | 6 months |
Countries
United States
Contacts
Primary ContactChris Cunningham, PhD
Outcome results
None listed